These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33952317)

  • 1. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
    Downs BM; Ding W; Cope LM; Umbricht CB; Li W; He H; Ke X; Holdhoff M; Bettegowda C; Tao W; Sukumar S
    Clin Epigenetics; 2021 May; 13(1):104. PubMed ID: 33952317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
    Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
    Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Array-based DNA methylation profiling of primary lymphomas of the central nervous system.
    Richter J; Ammerpohl O; Martín-Subero JI; Montesinos-Rongen M; Bibikova M; Wickham-Garcia E; Wiestler OD; Deckert M; Siebert R
    BMC Cancer; 2009 Dec; 9():455. PubMed ID: 20025734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of multiple genes in primary CNS lymphoma.
    Chu LC; Eberhart CG; Grossman SA; Herman JG
    Int J Cancer; 2006 Nov; 119(10):2487-91. PubMed ID: 16858686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
    Ohno M; Matsuzaki J; Kawauchi J; Aoki Y; Miura J; Takizawa S; Kato K; Sakamoto H; Matsushita Y; Takahashi M; Miyakita Y; Ichimura K; Narita Y; Ochiya T
    JAMA Netw Open; 2019 Dec; 2(12):e1916953. PubMed ID: 31808923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
    Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
    Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
    Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
    Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
    Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
    Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system lymphoma.
    Bhagavathi S; Wilson JD
    Arch Pathol Lab Med; 2008 Nov; 132(11):1830-4. PubMed ID: 18976024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
    De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
    Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.